➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Harvard Business School
McKesson
Merck
Johnson and Johnson

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,354,902

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,354,902
Title:Recombinant lactoferrins, methods of production from plants and uses thereof
Abstract: The invention concerns the use of a recombinant nucleotide sequence containing a cDNA coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by said cDNA, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins.
Inventor(s): Legrand; Dominique (Villeneuve d\'Ascq, FR), Salmon; Valerie (Montville, FR), Spik; Genevieve (Marcq en Baroeul, FR), Gruber; Veronique (Chamalieres, FR), Bournat; Philippe (Clermont-Ferrand, FR), Merot; Bertrand (Volvic, FR)
Assignee: Meristem Therapeutics S.A. (Clermont-Ferrand, FR)
Application Number:10/446,234
Patent Claims:1. A mature lactoferrin obtained by a method of producing lactoferrin comprising: (a) transforming plant cells so as to integrate a recombinant nucleotide sequence within the genome of the plant cells, the plant cells selected from the group consisting of maize, wheat, barley and rice cells, and the recombinant nucleotide sequence comprising: (i) a coding sequence for the mature lactoferrin, (ii) a transcription promoter and terminator which are operably linked to the coding sequence of (i) and are recognized by transcriptional machinery of plant cells, and (iii) a coding sequence for a signal peptide that directs secretion of recombinant peptides from plant cells, (b) expressing lactoferrin in said transformed plant cells, and (c) recovering the lactoferrin expressed in said transformed plant cells, wherein the expressed lactoferrin is mature lactoferrin.

2. The lactoferrin of claim 1, wherein the coding sequence for the lactoferrin is a coding sequence for human lactoferrin.

3. The lactoferrin of claim 1, wherein the coding sequence for a signal peptide is a sequence selected from the group consisting of a coding sequence for a signal peptide of lactoferrin, a coding sequence for the signal peptide of sweet potato sporamin A and a coding sequence for PRS (pathogenesis related protein).

4. The lactoferrin of claim 1, wherein the terminator is selected from the group consisting of the terminator polyA 35S of the CaMV (cauliflower mosaic virus), and the terminator polyA NOS of Agrobacterium tumefaciens and is located downstream of the coding sequence for the mature lactoferrin.

5. The lactoferrin of claim 1, wherein the transcription promoter is selected from the group consisting of the 35S promoter of the CaMV, the double constitutive promoter of the CaMV, the promoter pCRU of the radish cruciferin gene, the promoters pGA1 and pGA6 of Arabidopsis thaliana, the chimeric promoter super-promoter PSP of Agrobacterium tumefaciens, the rice actin promoter followed by the actin intron PAR-IRA promoter, the wheat HMWG promoter, and the maize gamma-zein promoter.

6. The lactoferrin of claim 1, wherein the recovering of the recombinant lactoferrin is by extraction followed by purification.

7. The lactoferrin of claim 1, wherein the transforming of plant cells is by means of Agrobacterium tumefaciens transformed by a vector containing the recombinant sequence.

8. The lactoferrin of claim 1, wherein: the coding sequence for the mature lactoferrin is the coding sequence for human lactoferrin, the coding sequence for a signal peptide is the coding sequence for the signal peptide of sweet potato sporamin A, the terminator is the terminator polyA 35S of the CaMV, and the transcription promoter is the wheat HMWG promoter.

9. A biomaterial or a pharmaceutical, medical, odontological, cosmetic or biotechnological composition which comprises the lactoferrin of claim 1.

10. A mature lactoferrin obtained by a method of producing lactoferrin comprising: (a) transforming plant cells so as to integrate a recombinant nucleotide sequence within the genome of the plant cells, the plant cells selected from the group consisting of maize, wheat, barley and rice cells, and the recombinant nucleotide sequence comprising: (i) a coding sequence for the mature lactoferrin, (ii) a transcription promoter and terminator which are operably linked to the coding sequence of (i) and are recognized by transcriptional machinery of plant cells, and (iii) a coding sequence for a signal peptide that directs secretion of recombinant peptides from plant cells, (b) producing transformed plants from the transformed plant cells, (c) expressing lactoferrin from said transformed plants, and (d) recovering the lactoferrin expressed from said transformed plants, wherein the expressed lactoferrin is mature lactoferrin.

11. The lactoferrin of claim 10, wherein the coding sequence for the lactoferrin is a coding sequence for human lactoferrin.

12. The lactoferrin of claim 10, wherein the coding sequence for a signal peptide is a sequence selected from the group consisting of a coding sequence for a signal peptide of lactoferrin, a coding sequence for the signal peptide of sweet potato sporamin A and a coding sequence for PRS.

13. The lactoferrin of claim 10, wherein the terminator is selected from the group consisting of the terminator polyA 35S of the CaMV, and the terminator polyA NOS of Agrobacterium tumefaciens and is located downstream of the coding sequence for the mature lactoferrin.

14. The lactoferrin of claim 10, wherein the transcription promoter is selected from the group consisting of the 35S promoter of the CaMV, the double constitutive promoter of the CaMV, the promoter pCRU of the radish cruciferin gene, the promoters pGA1 and pGA6 of Arabidopsis thaliana, the chimeric promoter super-promoter PSP of Agrobacterium tumefaciens, the rice actin promoter followed by the actin intron PAR-IRA promoter, the wheat HMWG promoter, and the maize gamma-zein promoter.

15. The lactoferrin of claim 10, wherein the recovering of the recombinant lactoferrin is by extraction followed by purification.

16. The lactoferrin of claim 10, wherein the transforming of plant cells is by means of Agrobacterium tumefaciens transformed by a vector containing the recombinant sequence.

17. The lactoferrin of claim 10, wherein: the coding sequence for the mature lactoferrin is the coding sequence for human lactoferrin, the coding sequence for a signal peptide is the coding sequence for the signal peptide of sweet potato sporamin A, the terminator is the terminator polyA 35S of the CaMV, and the transcription promoter is the wheat HMWG promoter.

18. A biomaterial or a pharmaceutical, medical, odontological, cosmetic or biotechnological composition which comprises the lactoferrin of claim 10.

Details for Patent 7,354,902

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,354,902

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.